DIAGENS

Based in Hangzhou, China, and established in 2016, Hangzhou Diagens Biotechnology Co. , Ltd. , trading as DIAGENS, is a medical equipment company focusing on the reproductive field. The company has built R&D, exhibition, office, and GMP production sites of nearly 50,000 square meters, and has undertaken 8 national and provincial-level research projects.

It acquired CE certification from the European Union, with more than 40 intellectual property rights in the United States, Europe, China, and other places. The company established cooperation with universities, such as Zhejiang University, Shanghai Jiaotong University, and Central South University. In March 2026, DIAGENS raised nearly HKD 792 million in an IPO, selling approximately 8 million shares at HKD 99 apiece on the Hong Kong Exchanges and Clearing (HKEX) under the ticker "2526". The company's products can be divided into Auto Vision Intelligent chromosome karyotype analysis system, the first generation cell culture medium, assisted reproduction consumables, MetaSight automatic cell microscopic image scanning system, and cytogenetics reagents.

The Auto Vision Intelligent chromosome karyotype analysis system and MetaSight automatic cell microscopic image scanning system were used by dozens of tertiary hospitals for analysis. The assisted reproduction consumable products include microinjection needles, special dishes for micro-fertilization, embryo freezing, and resuscitation fluids. The company generates revenue by selling AI‑powered medical imaging software, medical diagnostic devices, and related laboratory reagents and consumables to hospitals and clinical laboratories.